FSD Pharma Inc.

HUGE

CA35954B4047

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 11:00:28 2024-06-05 EDT			5-day change	1st Jan Change
0.375 ^CAD	-3.85%		-17.58%	-68.75%

06-04	FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	CI
05-28	FSD Pharma Slightly Lower In US Premarket As Submits Clinical Trial Protocol to Study Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	MT

FSD Pharma Inc. Elects Fernando Cugliari as Director

June 27, 2022 at 08:38 am

FSD Pharma Inc. elected Fernando Cugliari as director, at its AGM held on June 23, 2022.

Latest news about FSD Pharma Inc.

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	06-04	CI
FSD Pharma Slightly Lower In US Premarket As Submits Clinical Trial Protocol to Study Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	05-28	MT
FSD Pharma Inc. Submits A Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	05-28	CI
FSD Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia	05-07	CI
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	04-30	CI
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	04-25	MT
FSD Pharma Receives Nasdaq Non-Compliance Notice	04-08	MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	03-27	MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	03-27	MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	03-11	MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	03-11	CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	03-05	MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	03-05	MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	03-05	MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	03-05	CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma	02-19	MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	02-06	MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million	02-06	MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million	02-06	MT
FSD Pharma Inc. Announces Board Changes	01-29	CI
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus	12-27	MT
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding	12-04	CI
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp.	11-28	CI

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FSD PHARMA INC.	-68.75%	11.43M
VERTEX PHARMACEUTICALS INCORPORATED	+17.97%	123B
REGENERON PHARMACEUTICALS, INC.	+14.77%	107B
BIONTECH SE	-4.51%	24.01B
ARGENX SE	+2.18%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-41.04%	16.84B
BEIGENE, LTD.	-12.21%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+2.50%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.80%	11.32B